Xtant Medical Partners with Dilon Technologies for HEMOBLAST® Bellows Distribution Rights
- Xtant Medical Holdings partners with Dilon Technologies for exclusive distribution rights of HEMOBLAST® Bellows.
- The partnership aims to enhance Xtant Medical's market presence in hemostatic products.
- This strategic move focuses on expanding Xtant Medical’s product offerings and competitiveness.
Xtant Medical Holdings, Inc. announces a pivotal development in its strategic initiatives by entering into an exclusive distribution agreement with Dilon Technologies, Inc. for the HEMOBLAST® Bellows product. This innovative hemostatic solution is tailored for high-performance bleeding control during surgical procedures, specifically addressing scenarios where traditional methods may fall short. By securing these U.S. distribution rights, Xtant establishes a foothold in the burgeoning market for hemostatic products, estimated at $2.0 billion.
Enhancing Commercial Capabilities
Xtant’s President and CEO, Sean Browne, articulates a vision for the integration of Dilon’s experienced sales team, which comprises around 20 professionals. This strategic move is poised to amplify Xtant's commercial capabilities significantly while expanding its portfolio of surgical offerings. The HEMOBLAST Bellows is distinguished by its unique formulation, which includes a combination of collagen, human-derived thrombin, and bovine-derived chondroitin sulfate, designed to provide effective support across a range of bleeding situations.
User-Friendly and Effective Hemostasis
The HEMOBLAST product is delivered through a pre-loaded applicator that necessitates no preparation, enhancing its user-friendliness for surgical teams. George Makhoul, CEO of Dilon Technologies, expresses confidence in Xtant as an ideal partner to unlock the full potential of HEMOBLAST in the U.S. market. This collaboration reinforces Xtant's dedication to meeting the diverse needs of patients and healthcare professionals, solidifying its position as a leader in innovative surgical solutions.
Outlook for Future Growth
Looking ahead, Xtant plans to update its financial guidance for the full year 2026 during its upcoming first-quarter earnings report, illustrating the anticipated benefits of this distribution agreement. Through these strategic initiatives, Xtant Medical Holdings continues to underscore its commitment to enhancing surgical care through innovative medical technologies.